City Holding Co. Purchases 129 Shares of DaVita Inc. (NYSE:DVA)

City Holding Co. grew its position in shares of DaVita Inc. (NYSE:DVA) by 2.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,510 shares of the company’s stock after purchasing an additional 129 shares during the period. City Holding Co.’s holdings in DaVita were worth $690,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Wedge Capital Management L L P NC lifted its stake in DaVita by 17.1% during the first quarter. Wedge Capital Management L L P NC now owns 259,906 shares of the company’s stock worth $39,758,000 after purchasing an additional 37,899 shares during the last quarter. UMB Bank n.a. lifted its stake in DaVita by 65.5% during the first quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $29,000 after purchasing an additional 76 shares during the last quarter. Wedmont Private Capital lifted its stake in DaVita by 17.8% during the first quarter. Wedmont Private Capital now owns 2,095 shares of the company’s stock worth $326,000 after purchasing an additional 317 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. lifted its stake in DaVita by 23.6% during the first quarter. Thurston Springer Miller Herd & Titak Inc. now owns 2,015 shares of the company’s stock worth $308,000 after purchasing an additional 385 shares during the last quarter. Finally, Czech National Bank lifted its stake in DaVita by 3.3% during the first quarter. Czech National Bank now owns 10,106 shares of the company’s stock worth $1,546,000 after purchasing an additional 327 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

DVA has been the subject of a number of recent research reports. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Truist Financial lowered their target price on DaVita from $170.00 to $164.00 and set a “hold” rating for the company in a research note on Monday, May 19th. Sanford C. Bernstein set a $184.00 target price on DaVita in a research note on Friday, February 21st. Barclays boosted their target price on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. Finally, Cowen reissued a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $164.50.

DaVita Stock Down 0.1%

Shares of NYSE:DVA opened at $137.76 on Tuesday. DaVita Inc. has a 1 year low of $131.76 and a 1 year high of $179.60. The company has a market cap of $10.40 billion, a PE ratio of 12.83, a P/E/G ratio of 1.07 and a beta of 1.11. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The stock’s 50-day moving average is $142.23 and its 200 day moving average is $151.79.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The company had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.22 billion. During the same quarter in the previous year, the business earned $2.26 EPS. DaVita’s revenue was up 5.0% compared to the same quarter last year. Sell-side analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.